| Autor: |
Uy, Geoffrey L., Rettig, Michael P., Vey, Norbert, Godwin, John, Foster, Matthew C, Rizzieri, David A., Arellano, Martha L., Topp, Max S., Huls, Gerwin, Jongen-Lavrencic, Mojca, Martinelli, Giovanni, Paolini, Stefania, Ciceri, Fabio, Carrabba, Matteo Giovanni, Sweet, Kendra L., Ravandi, Farhad, Church, Sarah E., Vadakekolathu, Jayakumar, Rutella, Sergio, Sun, Jichao, Yang, Kang, Baughman, Jan, Curtis, Teia, Timmeny, Erin, Cali, Kerri, Tran, Kathy, Muth, John, La Motte-Mohs, Ross, Poirot, Camille, Pallis, Athanasios, Cesano, Alessandra, Bonvini, Ezio, Wigginton, Jon, Lowenberg, Bob, Davidson-Moncada, Jan K, DiPersio, John F. |
| Zdroj: |
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p764-764, 1p |
| Abstrakt: |
Acute myeloid leukemia (AML) blasts and leukemia stem cells highly express the α chain of the IL-3 receptor (CD123), compared to normal hematopoietic stem cells. CD123 expression is associated with high-risk features, increased risk of induction failure and poor prognosis (Vergez F, et al. Haematologica 2011; 96: 1792-8). Flotetuzumab (FLZ), a CD123 × CD3 bispecific DART molecule, is being tested in a phase 1/2 study in patients with relapsed/refractory (R/R) AML. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
